Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.

Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl-Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P.

Wien Klin Wochenschr. 2019 Jul 18. doi: 10.1007/s00508-019-1526-1. [Epub ahead of print]

PMID:
31321531
2.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch I, Haferlach C, Kubicek S, Mayerhoefer M, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402. [Epub ahead of print]

PMID:
31292114
3.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986. [Epub ahead of print]

4.

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.

Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class SV, Eisenwort G, Simonitsch-Klupp I, Esterbauer H, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G.

Haematologica. 2019 Apr 24. pii: haematol.2019.217950. doi: 10.3324/haematol.2019.217950. [Epub ahead of print]

5.

Identification of a leukemia-initiating stem cell in human mast cell leukemia.

Eisenwort G, Sadovnik I, Schwaab J, Jawhar M, Keller A, Stefanzl G, Berger D, Blatt K, Hoermann G, Bilban M, Willmann M, Winding C, Sperr WR, Arock M, Rülicke T, Reiter A, Valent P.

Leukemia. 2019 Apr 5. doi: 10.1038/s41375-019-0460-6. [Epub ahead of print]

PMID:
30953030
6.

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, Germing U, Sperr WR, Reiter A, Wolf D, Arock M, Haferlach T, Horny HP.

Int J Mol Sci. 2019 Feb 12;20(3). pii: E789. doi: 10.3390/ijms20030789. Review.

7.

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.

Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, Krall N, Pemovska T, Araghi M, Snijder B, Hubmann R, Ringler A, Runggatscher K, Demirtas D, de la Fuente OL, Hilgarth M, Skrabs C, Porpaczy E, Gruber M, Hoermann G, Kubicek S, Staber PB, Shehata M, Superti-Furga G, Jäger U, Bock C.

Nat Chem Biol. 2019 Mar;15(3):232-240. doi: 10.1038/s41589-018-0205-2. Epub 2019 Jan 28.

PMID:
30692684
8.

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit).

Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrózek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Møller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G.

Cancer Med. 2018 Sep;7(9):4447-4455. doi: 10.1002/cam4.1733. Epub 2018 Aug 16.

9.

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P.

Blood. 2018 Nov 1;132(18):1936-1950. doi: 10.1182/blood-2018-02-833582. Epub 2018 Jul 17.

PMID:
30018080
10.

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Sep;130(17-18):517-529. doi: 10.1007/s00508-018-1355-7. Epub 2018 Jul 13. Review.

11.

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.

Arock M, Wedeh G, Hoermann G, Bibi S, Akin C, Peter B, Gleixner KV, Hartmann K, Butterfield JH, Metcalfe DD, Valent P.

Haematologica. 2018 Nov;103(11):1760-1771. doi: 10.3324/haematol.2018.195867. Epub 2018 Jul 5. Review.

12.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768.

PMID:
29907599
13.

Molecular imaging and molecular diagnostics: two sides of the same coin?

Hacker M, Hoermann G, Kenner L.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1645-1648. doi: 10.1007/s00259-018-4060-x. No abstract available.

PMID:
29860534
14.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

15.

Major response of PNH to an AML chemotherapy protocol.

Füreder W, Sperr WR, Gleixner K, Thalhammer R, Schwarzinger I, Hoermann G, Kornauth C, Grünberger B, Valent P.

Ann Hematol. 2018 Aug;97(8):1487-1488. doi: 10.1007/s00277-018-3307-8. Epub 2018 Mar 22. No abstract available.

PMID:
29568989
16.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

17.

High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB).

Gebhart J, Hofer S, Panzer S, Quehenberger P, Sunder-Plassmann R, Hoermann G, Eigenbauer E, Haslacher H, Kepa S, Kyrle PA, Eichinger S, Knöbl P, Eischer L, Mannhalter C, Ay C, Pabinger I.

Haemophilia. 2018 May;24(3):405-413. doi: 10.1111/hae.13422. Epub 2018 Feb 1.

PMID:
29388750
18.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

19.

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis.

Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G.

Clin Chem. 2018 Mar;64(3):547-555. doi: 10.1373/clinchem.2017.277897. Epub 2017 Dec 13.

20.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, Majeti R, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP.

EBioMedicine. 2017 Dec;26:17-24. doi: 10.1016/j.ebiom.2017.11.024. Epub 2017 Nov 26. Review.

21.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

22.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

23.

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.

Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T.

Exp Hematol. 2018 Jan;57:50-59.e6. doi: 10.1016/j.exphem.2017.09.012. Epub 2017 Oct 12.

PMID:
29031704
24.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

25.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

26.

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P.

Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.

27.

Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.

Edlinger L, Berger-Becvar A, Menzl I, Hoermann G, Greiner G, Grundschober E, Bago-Horvath Z, Al-Zoughbi W, Hoefler G, Brostjan C, Gille L, Moriggl R, Spittler A, Sexl V, Hoelbl-Kovacic A.

Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.

28.

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.

Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, Sliwa T, Poehnl R, Buxhofer-Ausch V, Strecker K, Hoermann G, Knoebl P, Jaeger U, Geissler K, Kundi M, Valent P.

Am J Hematol. 2017 Oct;92(10):E567-E574. doi: 10.1002/ajh.24847. Epub 2017 Aug 17.

29.

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P.

Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8.

30.

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner GH, Sperr WR, Kirchmair R, Wolf D.

Leuk Res. 2017 Aug;59:47-54. doi: 10.1016/j.leukres.2017.05.008. Epub 2017 May 12. Review.

PMID:
28549238
31.

Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

Sadovnik I, Herrmann H, Eisenwort G, Blatt K, Hoermann G, Mueller N, Sperr WR, Valent P.

Exp Hematol. 2017 Jul;51:17-24. doi: 10.1016/j.exphem.2017.04.003. Epub 2017 Apr 27. Review.

32.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

33.

Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation.

Schmidt RL, Jutz S, Goldhahn K, Witzeneder N, Gerner MC, Trapin D, Greiner G, Hoermann G, Steiner G, Pickl WF, Burgmann H, Steinberger P, Ratzinger F, Schmetterer KG.

Sci Rep. 2017 Feb 7;7:42191. doi: 10.1038/srep42191.

34.

Homozygous familial hypercholesterolemia: Summarized case reports.

Widhalm K, Benke IM, Fritz M, Geiger H, Helk O, Fritsch M, Hoermann G, Kostner G.

Atherosclerosis. 2017 Feb;257:86-89. doi: 10.1016/j.atherosclerosis.2017.01.002. Epub 2017 Jan 18.

PMID:
28126585
35.

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, Bergmann M, Staber PB, Porpaczy E, Einberger C, Heinz M, Hauswirth A, Raderer M, Pabinger I, Thalhammer R, Egle A, Wendtner CM, Follows G, Hoermann G, Quehenberger P, Jilma B, Jaeger U.

Leukemia. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2.

36.

CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Greiner G, Witzeneder N, Berger A, Schmetterer K, Eisenwort G, Schiefer AI, Roos S, Popow-Kraupp T, Müllauer L, Zuber J, Sexl V, Kenner L, Sperr WR, Valent P, Mayerhofer M, Hoermann G.

Blood. 2017 Jan 19;129(3):371-382. doi: 10.1182/blood-2016-09-739003. Epub 2016 Nov 16.

37.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

38.

Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.

Byrgazov K, Lucini CB, Berkowitsch B, Koenig M, Haas OA, Hoermann G, Valent P, Lion T.

Oncotarget. 2016 Nov 22;7(47):78083-78094. doi: 10.18632/oncotarget.12943.

39.

Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.

Taylor N, Kremser I, Auer S, Hoermann G, Greil R, Haschke-Becher E, Esterbauer H, Kenner L, Oberkofler H.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):e13-e20. doi: 10.1097/QAI.0000000000001223.

40.

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.

Byrgazov K, Kastner R, Gorna M, Hoermann G, Koenig M, Lucini CB, Ulreich R, Benesch M, Strenger V, Lackner H, Schwinger W, Sovinz P, Haas OA, van den Heuvel-Eibrink M, Niemeyer CM, Hantschel O, Valent P, Superti-Furga G, Urban C, Dworzak MN, Lion T.

Leukemia. 2017 Jan;31(1):237-240. doi: 10.1038/leu.2016.250. Epub 2015 Aug 30. No abstract available.

41.

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M.

Vet Comp Oncol. 2017 Dec;15(4):1240-1256. doi: 10.1111/vco.12260. Epub 2016 Aug 9.

42.

Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.

Bauer E, Schlederer M, Scheicher R, Horvath J, Aigner P, Schiefer AI, Kain R, Regele H, Hoermann G, Steiner G, Kenner L, Sexl V, Villunger A, Moriggl R, Stoiber D.

Oncotarget. 2016 Mar 15;7(11):12191-205. doi: 10.18632/oncotarget.7687.

43.

The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells.

Maj M, Hoermann G, Rasul S, Base W, Wagner L, Attems J.

J Diabetes Res. 2016;2016:1964634. doi: 10.1155/2016/1964634. Epub 2015 Dec 28.

44.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

45.

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Hoermann G, Greiner G, Valent P.

Mediators Inflamm. 2015;2015:869242. doi: 10.1155/2015/869242. Epub 2015 Oct 12. Review.

46.

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Campana R, Moritz K, Marth K, Neubauer A, Huber H, Henning R, Blatt K, Hoermann G, Brodie TM, Kaider A, Valent P, Sallusto F, Wöhrl S, Valenta R.

J Allergy Clin Immunol. 2016 Feb;137(2):601-609.e8. doi: 10.1016/j.jaci.2015.08.042. Epub 2015 Oct 28.

47.

The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation.

Prodinger J, Loacker LJ, Schmidt RL, Ratzinger F, Greiner G, Witzeneder N, Hoermann G, Jutz S, Pickl WF, Steinberger P, Marculescu R, Schmetterer KG.

J Leukoc Biol. 2016 Apr;99(4):583-94. doi: 10.1189/jlb.3A0315-135R. Epub 2015 Oct 23.

PMID:
26497245
48.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P.

Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20. Erratum in: Blood. 2018 Mar 22;131(12 ):1390.

49.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

50.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

Supplemental Content

Loading ...
Support Center